Zalicus Inc. (NASDAQ: ZLCS) today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
In the company’s study, Z160 demonstrated substantial bioavailability and solubility improvements using a novel, proprietary formulation technology.
Based on the data from this study, Zalicus plans to advance Z160 into Phase 2 clinical development for the treatment of neuropathic pain in the second half of 2012.
Mark H.N. Corrigan, MD, President and CEO of Zalicus, commented:
We are encouraged by the substantial bioavailability and solubility improvements achieved with the new formulation of Z160 tested in this study. These data provides us with the confidence that we can achieve appropriate and consistent exposure levels to evaluate Z160’s efficacy in pain and we look forward to beginning a Phase 2 clinical study in neuropathic pain in the second half of 2012.
245 First St.
Cambridge, MA 02142
Zalicus Inc. discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus performs its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for both company’s internal product pipeline and its collaborators.